TKNO vs. VNRX, ABIO, ICCC, AWH, CODX, OCX, DMTK, AXDX, ACHV, and AFMD
Should you be buying Alpha Teknova stock or one of its competitors? The main competitors of Alpha Teknova include VolitionRx (VNRX), ARCA biopharma (ABIO), ImmuCell (ICCC), Aspira Women's Health (AWH), Co-Diagnostics (CODX), OncoCyte (OCX), DermTech (DMTK), Accelerate Diagnostics (AXDX), Achieve Life Sciences (ACHV), and Affimed (AFMD). These companies are all part of the "medical" sector.
Alpha Teknova (NASDAQ:TKNO) and VolitionRx (NYSE:VNRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, community ranking, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.
Alpha Teknova currently has a consensus price target of $15.00, indicating a potential upside of 737.99%. VolitionRx has a consensus price target of $2.50, indicating a potential upside of 224.68%. Given Alpha Teknova's higher probable upside, analysts plainly believe Alpha Teknova is more favorable than VolitionRx.
Alpha Teknova has a net margin of -97.85% compared to VolitionRx's net margin of -4,379.67%. VolitionRx's return on equity of 0.00% beat Alpha Teknova's return on equity.
VolitionRx has lower revenue, but higher earnings than Alpha Teknova. Alpha Teknova is trading at a lower price-to-earnings ratio than VolitionRx, indicating that it is currently the more affordable of the two stocks.
Alpha Teknova has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, VolitionRx has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.
In the previous week, Alpha Teknova had 2 more articles in the media than VolitionRx. MarketBeat recorded 10 mentions for Alpha Teknova and 8 mentions for VolitionRx. VolitionRx's average media sentiment score of 0.74 beat Alpha Teknova's score of 0.23 indicating that VolitionRx is being referred to more favorably in the news media.
13.8% of Alpha Teknova shares are owned by institutional investors. Comparatively, 8.1% of VolitionRx shares are owned by institutional investors. 15.2% of Alpha Teknova shares are owned by insiders. Comparatively, 15.4% of VolitionRx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Alpha Teknova received 3 more outperform votes than VolitionRx when rated by MarketBeat users. Likewise, 33.33% of users gave Alpha Teknova an outperform vote while only 30.77% of users gave VolitionRx an outperform vote.
Summary
VolitionRx beats Alpha Teknova on 9 of the 17 factors compared between the two stocks.
Get Alpha Teknova News Delivered to You Automatically
Sign up to receive the latest news and ratings for TKNO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TKNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alpha Teknova Competitors List
Related Companies and Tools
